RS

Rajbir Singh

Director Designated Partner DIN 09026939
DIN 09026939 First appointment Mar 2021 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Rajbir Singh

Data last updated:

Rajbir Singh was a Designated Partner at Tesla Medlife Llp (2023–2025) and Additional Director at Alzan Pharmaceuticals Private Limited (2021). The companies operate in Business Services and Pharma.

DIN 09026939
Primary Designation Designated Partner
Industry Business Services
First Appointment 22 Mar 2021

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner03 Jul 20232023Active
Additional Director22 Mar 20212019₹11.09 Cr (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Tesla Medlife Llp
Alzan Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rajbir Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajbir Singh

Rajbir Singh was first appointed on 22 Mar 2021 as Additional Director at Alzan Pharmaceuticals Private Limited. The most recent appointment on record is 03 Jul 2023 at Tesla Medlife Llp.

Rajbir Singh held 2 earlier board appointments: Tesla Medlife Llp (Designated Partner, 03 Jul 2023 to 14 Jul 2025); Alzan Pharmaceuticals Private Limited (Additional Director, 22 Mar 2021 to 11 Oct 2021).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available